

## Jazz Is Committed to Removing Barriers to Access and Reimbursement

Jazz Pharmaceuticals provides support and tools to remove barriers to access for VYXEOS<sup>®</sup> (daunorubicin and cytarabine) for appropriate patients.

### Access and Reimbursement Managers Provide Personal Expertise and Support<sup>a</sup>

- Assistance with reimbursement-related questions about VYXEOS
- Purchasing, procurement, and distribution support, and education on coding and billing

For more information or assistance, please contact your Jazz Access and Reimbursement Manager.



### JazzCares Helps Appropriate Patients Get Access to VYXEOS

The JazzCares Program **provides dedicated JazzCares specialists to assist patients** who have started treatment with VYXEOS, either in the inpatient or outpatient settings.

- Benefits investigation<sup>a</sup> to help patients understand their existing insurance coverage for VYXEOS
- Prior authorization and appeals information support<sup>a</sup>
- Financial assistance programs for eligible patients<sup>b</sup>

For more information about JazzCares, **visit [www.JazzCares.com](http://www.JazzCares.com)** or call the **Patient Support Hotline at 1-855-5VYXEOS (1-855-589-9367)**, Monday through Friday between 8 AM and 8 PM ET, to speak with a representative.

<sup>a</sup>Insurance coverage and plans may vary. The JazzCares Program provides general information only and is not a guarantee of any coverage or reimbursement outcome. All treatment decisions rest solely with the treating physician or qualified health care professional.

<sup>b</sup>Subject to eligibility requirements and terms and conditions.

### Permanent, Product-Specific J-Code

Assigned January 1, 2019, the J-code **streamlines the billing and reimbursement process** for VYXEOS.



J-code	Dosage	Billing unit per dose	Billing unit per vial
J9153	Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine	1	44

### INDICATION

VYXEOS is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

### IMPORTANT SAFETY INFORMATION

**WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS**

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.

Please see next page for additional Important Safety Information and click [here](#) for Prescribing Information, including BOXED Warning.

## IMPORTANT SAFETY INFORMATION (cont.)

- VYXEOS is contraindicated in patients with a history of serious hypersensitivity reactions to cytarabine, daunorubicin, or any component of the formulation.
- Serious or fatal hemorrhage events, including fatal CNS hemorrhages, associated with prolonged severe thrombocytopenia, have occurred in patients treated with VYXEOS. Monitor blood counts regularly and administer platelet transfusion support as required.
- VYXEOS contains daunorubicin, which has a known risk of cardiotoxicity. Assess cardiac function before, during, and after treatment as clinically indicated. Discontinue in patients with impaired cardiac function unless the benefit of treatment outweighs the risk. VYXEOS treatment is not recommended in patients with cardiac function that is less than normal. Calculate the lifetime cumulative anthracycline exposure prior to each cycle of VYXEOS. VYXEOS is not recommended in patients who have reached the maximum lifetime anthracycline dose limit.
- If a severe or life-threatening hypersensitivity reaction occurs, discontinue VYXEOS permanently, treat according to the standard of care, and monitor until signs and symptoms resolve.
- VYXEOS contains copper and has the potential to cause copper overload in patients with Wilson's disease or other copper-related metabolic disorders. Monitor patients and use only if the benefits outweigh the risks. Discontinue in patients with signs or symptoms of acute copper toxicity.
- Daunorubicin has been associated with severe local tissue necrosis at the site of drug extravasation. Administer VYXEOS by the intravenous route only.
- VYXEOS can cause fetal harm. Advise females and males of reproductive potential of the potential risk to a fetus and to use effective contraception.
- The most common adverse reactions (incidence  $\geq 25\%$ ) were hemorrhagic events (74%), febrile neutropenia (70%), rash (56%), edema (55%), nausea (49%), mucositis (48%), diarrhea (48%), constipation (42%), musculoskeletal pain (43%), fatigue (39%), abdominal pain (36%), dyspnea (36%), headache (35%), cough (35%), decreased appetite (33%), arrhythmia (31%), pneumonia (31%), bacteremia (29%), chills (27%), sleep disorders (26%), and vomiting (25%).

Please click [here](#) for full Prescribing Information, including **BOXED Warning**.

To learn more about VYXEOS, please visit [www.VyxeosPro.com](http://www.VyxeosPro.com).

VYXEOS is a registered trademark of Jazz Pharmaceuticals, Inc.



© 2020 Jazz Pharmaceuticals plc or its subsidiaries  
US-VYX-2000247 Rev0920

**Vyxeos**<sup>®</sup>  
(daunorubicin and cytarabine) <sup>44 mg/100 mg</sup>  
liposome for injection <sub>per vial</sub>